Peptide-conjugate phage-mimicking nanoparticles for inflammation-free wound healing

Abstract

The antimicrobial nanoparticle comprises an internal silica core, gold (Au) nanospheres surrounding the internal silica core, a surface layer containing silver (Ag) or silver alloyed with the gold nanospheres surrounding the gold nanospheres, and an antimicrobial peptide conjugated to the surface layer, selected from the group consisting of cysteine-terminated Syn71 peptide, cysteine-terminated MC1-2 peptide, and cysteine-terminated Syn20 peptide.

Claims

1. Antibacterial nanoparticles: Internal silica core, Gold (Au) nanospheres surrounding the internal silica core, A surface layer containing silver (Ag) surrounding the gold nanospheres or silver alloyed with the gold nanospheres, The antimicrobial peptide conjugated to the surface layer is selected from the group consisting of cysteine-terminated Syn71 peptide, cysteine-terminated MC1-2 peptide, and cysteine-terminated Syn20 peptide. Antibacterial nanoparticles containing these nanoparticles.

2. The antimicrobial nanoparticle according to claim 1, wherein the antimicrobial peptide is the cysteine-terminated Syn71 peptide, and the cysteine-terminated Syn71 peptide contains the amino acid sequence CAGTEKIFQRLKKTIQEGKKIAKRWW (SEQ ID NO: 1).

3. The antimicrobial nanoparticle according to claim 1, wherein the antimicrobial peptide is the cysteine-terminal MC1-2 peptide, and the cysteine-terminal MC1-2 peptide comprises the amino acid sequence CSAVWRHWRRFWLRKRK (SEQ ID NO: 2).

4. The antimicrobial nanoparticle according to claim 1, wherein the antimicrobial peptide is a cysteine-terminated Syn20 peptide, and the cysteine-terminated Syn20 peptide contains the amino acid sequence CAWKKTIRQYLKNKIKKKGRKAVIAW (SEQ ID NO: 3).

5. The antibacterial nanoparticle according to claim 1, wherein the internal silica core has a silane-coated outer surface.

6. The antibacterial nanoparticles according to claim 1, wherein the average diameter of the nanoparticles is about 15 nm to about 30 nm.

7. The antibacterial nanoparticles according to claim 1, wherein the average diameter of the nanoparticles is about 90 nm to about 100 nm.

8. The Syn71 peptide is conjugated to the surface layer at an average concentration of approximately 40 μM to 60 μM; The MC1-2 peptide is conjugated to the surface layer at an average concentration of approximately 40 μM to approximately 60 μM; or The Syn20 peptide is conjugated to the surface layer at an average concentration of approximately 40 μM to approximately 60 μM. The antibacterial nanoparticles according to claim 1.

9. An antimicrobial composition comprising antimicrobial nanoparticles as described in claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.

10. The antimicrobial composition according to claim 9, comprising a group of antimicrobial nanoparticles having an average antimicrobial peptide of about 1 μM to about 150 μM conjugated to the surface layer.

11. The antibacterial composition according to claim 10, which is formulated as a topical cream or ointment.

12. A method for treating a bacterial infection in a subject having a bacterial infection, comprising administering an effective amount of antimicrobial nanoparticles according to claim 1 to the subject, wherein the antimicrobial nanoparticles reduce the spread of the bacterial infection by more than about 95%, kill the bacteria of the bacterial infection, or both, thereby treating the bacterial infection.

13. The method according to claim 12, wherein the bacterial cell is one or more of the following species: Enterococcus faecalis, Corynebacterium striatum, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Streptococcus pyogenes.

14. The method according to claim 12, wherein antimicrobial nanoparticles are administered locally or intravenously.

15. A medical bandage comprising antimicrobial nanoparticles according to any one of claims 1 to 8 or a composition according to any one of claims 9 to 11.

16. A method for treating a wound, comprising applying the medical bandage described in claim 15 to the wound.

17. A pharmaceutical product comprising antimicrobial nanoparticles according to any one of claims 1 to 8 or a composition according to any one of claims 9 to 11, wherein the pharmaceutical product is one or more of medical implants, dental implants, and surgical instruments.

18. The pharmaceutical product according to claim 17, wherein the antibacterial nanoparticles are arranged on the surface of the medical implant, the dental implant, and the surgical instrument.

Images